Correspondence  |   March 2019
In Reply
Author Notes
  • Division of Molecular Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California (M.E.). meghbali@ucla.edu
  • (Accepted for publication November 16, 2018.)
    (Accepted for publication November 16, 2018.)×
Article Information
Correspondence
Correspondence   |   March 2019
In Reply
Anesthesiology 3 2019, Vol.130, 519-521. doi:10.1097/ALN.0000000000002566
Anesthesiology 3 2019, Vol.130, 519-521. doi:10.1097/ALN.0000000000002566
We have carefully read the letters from Fettiplace et al. and Zaugg et al. regarding our paper1  and would like to respond to their comments.
In response to Fettiplace et al., we disagree that the study lacks appropriate controls for both the models used. For the bupivacaine model, we believe that we have all the controls needed, given that we investigated the possible effects of 30-min pretreatment of GW1100 on heart function before bupivacaine administration. For the ischemia-reperfusion injury model, we have two control groups: the ischemia-reperfusion group without lipid emulsion, and the GW1100 perfusion group without ischemia-reperfusion injury. We agree with both Fettiplace et al. and Zaugg et al. that having an additional control group of ischemia-reperfusion injury with GW1100 pretreatment would have shown potential effects of GW1100 pretreatment on post–ischemia-reperfusion cardiac function, if any.